




PHARMACEUTICAL 2017

Rezolute Inc.
Rank 199 of 292





PHARMACEUTICAL 2017

Rezolute Inc.
Rank 199 of 292

The relative strengths and weaknesses of Rezolute Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rezolute Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 236% points. The greatest weakness of Rezolute Inc. is the variable Net Income, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is 2.4%, being 0.56% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	4,492
Cost of Goods Sold	0
Intangible Assets	52
Liabilities, Current	1,730
Liabilities, Non-Current	400
Other Assets	375
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	16
Other Revenues	0
Property and Equipment	5,985
Research and Development	9,448
Selling, General and Administrative Expense	5,503

Output Variable	Value in 1000 USD
Assets	10,903
Liabilities	2,131
Expenses	14,951
Revenues	0
Stockholders Equity	8,773
Net Income	-14,936
Comprehensive Net Income	-14,936
Economic Capital Ratio	2.4%